Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This brand new book offers practical guidance on navigating this exciting area of converging technologies.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 25 September 2014 | By Alexander Gaffney, RAC,
New Jersey-based pharmaceutical manufacturer Pacira Pharmaceuticals has been sent a Warning Letter by the US Food and Drug Administration (FDA) after the regulator took issue with the way in which the company was promoting its analgesic drug Exparel.
FDA's letter, dated 22 September 2014, references "educational technique flashcards" and a journal advertisement the agency said created the impression that Exparel has been approved for "new uses for which it lacks approval" and overstates the efficacy of the drug for the purposes for which it has obtained approval.
The Warning Letter is relatively unusual, as FDA most often sends companies so-called "Untitled Letters" for perceived violations of its advertising regulations. The Warning Letter, sent by FDA's Office of Prescription Drug Promotion (OPDP), is one of just a small handful issued by the office since it changed its name from the Division of Drug Marketing, Advertising and Communications (DDMAC), according to FDA records.
FDA called Pacira's alleged violations "extremely concerning from a public health perspective."
FDA's concern is largely focused on the expansion of Exparel's claims. The drug has been studied and approved for use as an injectable local anesthetic agent after two specific surgeries: bunionectomy and hemorrhoidectomy.
However, FDA said the company's products indicated the drug had been used in specific surgical settings, such as in a laparoscopic cholecystectomy and an open colectomy. Neither surgical procedure is supported by data provided by Pacira, FDA said. Even disclosures in the company's materials did "not mitigate the overwhelming impression that Exparel is safe and effective for use in cholecystectomy and colectomy," FDA wrote.
FDA also said it was "concerned" about an "array of professionally-directed promotional materials" that implied the drug to be safe and effective in "various other surgical procedures."
"These additional materials suggest an extensive promotional campaign by Pacira to promote the use of Exparel in surgical procedures other than those for which the drug has been shown to be safe and effective," FDA wrote.
The letter goes on to also chide Pacira for allegedly implying that Exparel is more effective than it had been able to demonstrate through "substantial evidence" or "substantial clinical experience"—two metrics often used by FDA, and generally taken to mean evidence obtained through Phase III clinical trials. Pacira had claimed through its materials that Exparel controlled pain for up to 72 hours with a single dose."
"Pain control beyond 24 hours … has not been demonstrated," FDA observed.
FDA ordered the company to immediately cease violating federal regulations, and to issue corrective messaging to all affected audiences "for the same duration of time and with the same frequency that the promotional material was disseminated."
In a statement, Pacira said that it stood behind its claims.
"We take regulatory compliance very seriously and believe that our current labeling supports the claims being challenged by the FDA,” said Dave Stack, president, CEO and chairman of Pacira. The company plans to explain its "position" further to regulators, Stack added.
Warning Letter
Press Release
Tags: Warning Letter, Pacira, Exparel, OPDP, Advertising, Promotion
Regulatory Focus newsletters
All the biggest regulatory news and happenings.